112 related articles for article (PubMed ID: 31257851)
1. Peptide and Aptamer Decorated Delivery System for Targeting Delivery of Cas9/sgRNA Plasmid To Mediate Antitumor Genome Editing.
Liu BY; He XY; Xu C; Ren XH; Zhuo RX; Cheng SX
ACS Appl Mater Interfaces; 2019 Jul; 11(27):23870-23879. PubMed ID: 31257851
[TBL] [Abstract][Full Text] [Related]
2. Multifunctional Vector for Delivery of Genome Editing Plasmid Targeting β-Catenin to Remodulate Cancer Cell Properties.
He XY; Liu BY; Peng Y; Zhuo RX; Cheng SX
ACS Appl Mater Interfaces; 2019 Jan; 11(1):226-237. PubMed ID: 30540162
[TBL] [Abstract][Full Text] [Related]
3. Reversal of tumor malignization and modulation of cell behaviors through genome editing mediated by a multi-functional nanovector.
Liu BY; He XY; Zhuo RX; Cheng SX
Nanoscale; 2018 Dec; 10(45):21209-21218. PubMed ID: 30417194
[TBL] [Abstract][Full Text] [Related]
4. Tumor targeted genome editing mediated by a multi-functional gene vector for regulating cell behaviors.
Liu BY; He XY; Zhuo RX; Cheng SX
J Control Release; 2018 Dec; 291():90-98. PubMed ID: 30339905
[TBL] [Abstract][Full Text] [Related]
5. Cationic Polymer-Mediated CRISPR/Cas9 Plasmid Delivery for Genome Editing.
Zhang Z; Wan T; Chen Y; Chen Y; Sun H; Cao T; Songyang Z; Tang G; Wu C; Ping Y; Xu FJ; Huang J
Macromol Rapid Commun; 2019 Mar; 40(5):e1800068. PubMed ID: 29708298
[TBL] [Abstract][Full Text] [Related]
6. Aptamer/Peptide-Functionalized Genome-Editing System for Effective Immune Restoration through Reversal of PD-L1-Mediated Cancer Immunosuppression.
He XY; Ren XH; Peng Y; Zhang JP; Ai SL; Liu BY; Xu C; Cheng SX
Adv Mater; 2020 Apr; 32(17):e2000208. PubMed ID: 32147886
[TBL] [Abstract][Full Text] [Related]
7. A Dual-Targeting Delivery System for Effective Genome Editing and In Situ Detecting Related Protein Expression in Edited Cells.
Liu BY; He XY; Xu C; Xu L; Ai SL; Cheng SX; Zhuo RX
Biomacromolecules; 2018 Jul; 19(7):2957-2968. PubMed ID: 29617556
[TBL] [Abstract][Full Text] [Related]
8. Nonviral gene editing via CRISPR/Cas9 delivery by membrane-disruptive and endosomolytic helical polypeptide.
Wang HX; Song Z; Lao YH; Xu X; Gong J; Cheng D; Chakraborty S; Park JS; Li M; Huang D; Yin L; Cheng J; Leong KW
Proc Natl Acad Sci U S A; 2018 May; 115(19):4903-4908. PubMed ID: 29686087
[TBL] [Abstract][Full Text] [Related]
9. Scaffold-mediated non-viral delivery platform for CRISPR/Cas9-based genome editing.
Chin JS; Chooi WH; Wang H; Ong W; Leong KW; Chew SY
Acta Biomater; 2019 May; 90():60-70. PubMed ID: 30978509
[TBL] [Abstract][Full Text] [Related]
10. A multifunctional non-viral vector for the delivery of MTH1-targeted CRISPR/Cas9 system for non-small cell lung cancer therapy.
Wang Y; Tang Y; Zhao XM; Huang G; Gong JH; Yang SD; Li H; Wan WJ; Jia CH; Chen G; Zhang XN
Acta Biomater; 2022 Nov; 153():481-493. PubMed ID: 36162766
[TBL] [Abstract][Full Text] [Related]
11. A Nucleic Acid/Gold Nanorod-Based Nanoplatform for Targeted Gene Editing and Combined Tumor Therapy.
Tang W; Han L; Lu X; Wang Z; Liu F; Li Y; Liu S; Liu S; Tian R; Liu J; Ding B
ACS Appl Mater Interfaces; 2021 May; 13(18):20974-20981. PubMed ID: 33909408
[TBL] [Abstract][Full Text] [Related]
12. Direct Cytosolic Delivery of CRISPR/Cas9-Ribonucleoprotein for Efficient Gene Editing.
Mout R; Ray M; Yesilbag Tonga G; Lee YW; Tay T; Sasaki K; Rotello VM
ACS Nano; 2017 Mar; 11(3):2452-2458. PubMed ID: 28129503
[TBL] [Abstract][Full Text] [Related]
13. Artificial Virus Delivers CRISPR-Cas9 System for Genome Editing of Cells in Mice.
Li L; Song L; Liu X; Yang X; Li X; He T; Wang N; Yang S; Yu C; Yin T; Wen Y; He Z; Wei X; Su W; Wu Q; Yao S; Gong C; Wei Y
ACS Nano; 2017 Jan; 11(1):95-111. PubMed ID: 28114767
[TBL] [Abstract][Full Text] [Related]
14. A non-cationic nucleic acid nanogel for the delivery of the CRISPR/Cas9 gene editing tool.
Ding F; Huang X; Gao X; Xie M; Pan G; Li Q; Song J; Zhu X; Zhang C
Nanoscale; 2019 Oct; 11(37):17211-17215. PubMed ID: 31531437
[TBL] [Abstract][Full Text] [Related]
15. A novel dual-targeting delivery system for specific delivery of CRISPR/Cas9 using hyaluronic acid, chitosan and AS1411.
Khademi Z; Ramezani M; Alibolandi M; Zirak MR; Salmasi Z; Abnous K; Taghdisi SM
Carbohydr Polym; 2022 Sep; 292():119691. PubMed ID: 35725215
[TBL] [Abstract][Full Text] [Related]
16. Ultra-efficient delivery of CRISPR/Cas9 using ionic liquid conjugated polymers for genome editing-based tumor therapy.
Huang Z; Yang T; Yu J; Gao Y; Weng Y; Huang Y; Li S
Biomater Sci; 2024 Mar; 12(7):1716-1725. PubMed ID: 38344762
[TBL] [Abstract][Full Text] [Related]
17. Baculoviral delivery of CRISPR/Cas9 facilitates efficient genome editing in human cells.
Hindriksen S; Bramer AJ; Truong MA; Vromans MJM; Post JB; Verlaan-Klink I; Snippert HJ; Lens SMA; Hadders MA
PLoS One; 2017; 12(6):e0179514. PubMed ID: 28640891
[TBL] [Abstract][Full Text] [Related]
18. A targeting delivery system for effective genome editing in leukemia cells to reverse malignancy.
Ren XH; Xu C; Li LL; Zuo Y; Han D; He XY; Cheng SX
J Control Release; 2022 Mar; 343():645-656. PubMed ID: 35157940
[TBL] [Abstract][Full Text] [Related]
19. Identifying Signalling Pathways Regulated by GPRC5B in β-Cells by CRISPR-Cas9-Mediated Genome Editing.
Atanes P; Ruz-Maldonado I; Hawkes R; Liu B; Persaud SJ; Amisten S
Cell Physiol Biochem; 2018; 45(2):656-666. PubMed ID: 29408822
[TBL] [Abstract][Full Text] [Related]
20. Biomimetic gene editing system for precise tumor cell reprogramming and augmented tumor therapy.
Qiao L; Gao M; Yi X; Peng H; Zhang R; Yao W; Sun G; He X
J Control Release; 2023 Apr; 356():663-677. PubMed ID: 36924897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
